Sidoti Events, LLC's Virtual June Small-Cap Conference

$AGI
$ALUR
$ATOS
$BRC
Precious Metals
Basic Materials
Medical/Dental Instruments
Health Care
Get the next $AGI alert in real time by email

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference taking place Wednesday and Thursday, June 12-13, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.

Presentation Schedule

*All Times EDT

Wednesday, June 12, 2024 (Day 1)

8:30-9:00

*****

*****

InfuSystem Holdings Inc. (INFU)

*****

9:15-9:45

*****

ECD Automotive (ECDA)

Lifeward [ReWalk Robotics] (LFWD)

*****

10:00-10:30

Unisys Corporation (UIS)

*****

Myomo, Inc (MYO)

Drilling Tools International Corp. (DTI)

10:45-11:15

American Software (AMSWA)

USANA Health Sciences (USNA)

Assertio Holdings, Inc. (ASRT)

Information Services Group ["ISG"] (III)

11:30-12:00

Vishay Precision Group (VPG)

Global Industrial Company (GIC)

Zomedica Corp. (ZOM)

Charles River Associates (CRAI)

12:15-12:45

Quad/Graphics Inc (QUAD)

*****

RadNet, Inc. (RDNT)

*****

1:00-1:30

*****

Rayonier Advanced Materials ["RYAM"] (RYAM)

Superior Group of Companies (SGC)

Portman Ridge Finance Corp (PTMN)

1:45-2:15

*****

Electromed (ELMD)

Senseonics Holdings, Inc. (SENS)

BioLargo, Inc. (BLGO)

2:30-3:00

A10 Networks, Inc. (ATEN)

Granite Ridge Resources, Inc. (GRNT)

Theravance Biopharma (TBPH)

ARC Document Solutions (ARC)

3:15-3:45

GlucoTrack Inc. (GCTK)

Canoo (GOEV)

Bitcoin Depot (BTM)

Topaz Energy Corp (TSX:TPZ)

4:00-4:30

Intelligent Bio Solutions (INBS)

Brilliant Earth Group, Inc. (BRLT)

Oportun Financial Corp. (OPRT)

TrueBlue (TBI)

1x1s Only

(12th)

GATX Corporation (GATX)

Hillenbrand (HI)

MYR Group Inc. (MYRG)

Pitney Bowes (PBI)

Primoris Services Corporation (PRIM)

Sonendo (SONX)

Titan International, Inc. (TWI)

*****

*All Times EDT

Thursday, June 13, 2024 (Day 2)

8:30-9:00

GDEV Inc. (GDEV)

*****

Meihua Intl. Medical Technologies Co. (MHUA)

*****

9:15-9:45

Commercial Vehicle Group (CVGI)

Atossa Therapeutics (ATOS)

Citius Pharmaceuticals, Inc. (CTXR)

*****

10:00-10:30

Paysign, Inc. (PAYS)

Graham Corporation (GHM)

Allurion (ALUR)

Mobile Infrastructure (BEEP)

10:45-11:15

*****

Genco Shipping & Trading Ltd (GNK)

VAREX IMAGING (VREX)

Nature's Sunshine (NATR)

11:30-12:00

*****

Brady Corporation (BRC)

BioHarvest Sciences Inc. (CNVCD)

Hovnanian Enterprises Inc (HOV)

12:15-12:45

*****

Great Lakes Dredge & Dock Corp. (GLDD)

*****

CES Energy Solutions (CEU-TSX)

1:00-1:30

Sonim Technologies Inc. (SONM)

Amerigo Resources (ARREF)

*****

The Real Brokerage Inc (REAX)

1:45-2:15

*****

NN Inc. (NNBR)

*****

Consumer Portfolio Services (CPSS)

2:30-3:00

*****

Alamos Gold Inc. (AGI)

GoHealth (GOCO)

Resources Connection, Inc. (RGP)

1x1s Only

(13th)

Belden Inc. (BDC)

CSW Industrials (CSWI)

Federal Signal Corporation (FSS)

HNI Corporation (HNI)

OneSpan Inc. (OSPN)

Plexus Corp. (PLXS)

Sonendo (SONX)

*****

About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")
In 2023, Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti's coverage universe comprises approximately 150 equities of which greater than 60 percent participate in the firm's rapidly growing Company Sponsored Research ("CSR") program. In 2024, Sidoti established Lighthouse Equity Research as an extension of its CSR program to meet the specific needs of companies not valued using traditional metrics or that face challenges obtaining coverage due to political risks or other factors. Events is a leading provider of corporate access through the eight investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Event's benefits from Sidoti's small- and microcap-focused nationwide sales force, which has connections with 2,500 institutional relationships in North America. This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.

SOURCE: Sidoti Events, LLC



View the original press release on accesswire.com

Get the next $AGI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AGI
$ALUR
$ATOS
$BRC

CompanyDatePrice TargetRatingAnalyst
2/14/2025$362.00Hold
Truist
2/4/2025$152.00Hold
Stifel
12/30/2024$9.00Hold → Buy
D. Boral Capital
12/6/2024$450.00Neutral
Goldman
12/3/2024Sector Perform → Outperform
National Bank Financial
11/25/2024$425.00Equal Weight
Wells Fargo
11/14/2024Buy → Neutral
Chardan Capital Markets
10/23/2024$26.00 → $17.00Buy → Hold
Stifel
More analyst ratings

$AGI
$ALUR
$ATOS
$BRC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

    $ALUR
    Medical/Dental Instruments
    Health Care
  • REMINDER: Dry Bulk Shipping Industry Leaders Presenting at Capital Link's 19th Annual International Shipping Forum - Monday, March 31, 2025, New York City

    NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Senior executives from leading Dry Bulk shipping companies will participate in panels and presentations at the 19th Annual Capital Link International Shipping Forum on Monday, March 31, 2025, at the Metropolitan Club in New York City. The event is organized in cooperation with NASDAQ & NYSE. The Forum features a series of panel discussions as well as 1x1 meetings between investors and executives from shipping companies. LUNCHEON KEYNOTE SPEAKER Mr. Evangelos Marinakis, Chairman & CEO of Capital Maritime & Trading Corp. will deliver the Luncheon Keynote Remarks.Introductory Remarks by Mr. Chris Taylor, Chief Development Officer of NYSE G

    $DSX
    $GNK
    $PANL
    $SB
    Marine Transportation
    Consumer Discretionary
  • Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

    Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AGI
$ALUR
$ATOS
$BRC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AGI
$ALUR
$ATOS
$BRC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AGI
$ALUR
$ATOS
$BRC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AGI
$ALUR
$ATOS
$BRC
Leadership Updates

Live Leadership Updates

See more
  • Alamos Gold Appoints J. Robert S. Prichard as Chair of the Board

    TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (TSX:AGI; NYSE:AGI), (TSX:AGI; NYSE:AGI) today announced the appointment of J. Robert S. Prichard as Chair of the Board of Directors, effective January 8, 2025. Mr. Prichard will succeed Paul Murphy, who sadly passed away in December 2024 after serving on the Board for over 14 years, and as Chairman for the past nine years. J. Robert S. Prichard has been a member of the Alamos Board for nearly six years, having joined in May 2019. Mr. Prichard is a lawyer, non-executive Chairman of Torys LLP, Director of Onex Corporation, Wittington Investments Limited, Chair of VIA HFR, and Vice Chair of the Rideau Hall Foundation. He is the for

    $AGI
    Precious Metals
    Basic Materials
  • Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

    Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12

    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

    SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial

    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AGI
$ALUR
$ATOS
$BRC
Financials

Live finance-specific insights

See more
  • Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

    $ALUR
    Medical/Dental Instruments
    Health Care
  • Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

    Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

    SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-

    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AGI
$ALUR
$ATOS
$BRC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more